Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.40 |
| ▸ | IDO1 | P14902 | 3/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8700783 | 1.00 | TACR1 (0.40) | TACR1IDO1TDO2CES2TACR3 | |
| SCHEMBL264836 | 1.00 | TACR1 (0.40) | TACR1IDO1TDO2CES2TACR3 | |
| SCHEMBL15161876 | 0.90 | PDE2A (0.40) | TACR1IDO1TDO2CES2TACR3 | |
| SCHEMBL271091 | 0.87 | RAPGEF4 (0.38) | TACR1IDO1TDO2TACR3MAPT | |
| SCHEMBL31749745 | 0.87 | TACR1 (0.33) | TACR1IDO1TDO2PDE2A | |
| SCHEMBL3588498 | 0.87 | NOTUM (0.42) | TACR1IDO1TDO2TACR3PDE2A | |
| SCHEMBL1295467 | 0.87 | TACR1 (0.33) | TACR1IDO1TDO2PDE2A | |
| SCHEMBL3584929 | 0.87 | NOTUM (0.42) | TACR1IDO1TDO2TACR3PDE2A | |
| SCHEMBL15216806 | 0.87 | RAPGEF4 (0.38) | TACR1IDO1TDO2TACR3MAPT | |
| SCHEMBL27906515 | 0.86 | RAPGEF4 (0.39) | TACR1IDO1TDO2RAPGEF4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9272966-B2 | Method for preparing optically active 1-bromo-1[3,5-bis(trifluoromethyl)phenyl]ethane | KOWA COMPANY, LTD. (JP) | 2016-03-01 | — | — | US | claimed |
| US-20130190540-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE 1-BROMO-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHANE | KOWA COMPANY, LTD. (JP) | 2013-07-25 | — | — | US | claimed |
| EP-2597079-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 1-BROMO-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHANE | Kowa Company Ltd. (JP) | 2013-05-29 | — | — | EP | claimed |
| EP-2578574-B1 | OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE, AND MANUFACTURING METHOD FOR SAME | KOWA CO (JP) | 2016-04-27 | — | — | EP | disclosed |
| EP-2578574-B1 | OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE, AND MANUFACTURING METHOD FOR SAME | KOWA CO (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-9272966-B2 | Method for preparing optically active 1-bromo-1[3,5-bis(trifluoromethyl)phenyl]ethane | KOWA COMPANY, LTD. (JP) | 2016-03-01 | — | — | US | disclosed |
| US-20150320748-A1 | AGENT FOR INHIBITING EXPRESSION OF LIPID METABOLISM RELATED MRNA | KOWA CO., LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20150320748-A1 | AGENT FOR INHIBITING EXPRESSION OF LIPID METABOLISM RELATED MRNA | KOWA CO., LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20150306098-A1 | AGENT FOR INHIBITING EXPRESSION OF LIPID METABOLISM RELATED MRNA | KOWA CO., LTD. (JP) | 2015-10-29 | — | — | US | disclosed |
| US-20150306098-A1 | AGENT FOR INHIBITING EXPRESSION OF LIPID METABOLISM RELATED MRNA | KOWA CO., LTD. (JP) | 2015-10-29 | — | — | US | disclosed |
| US-8906895-B2 | Optically active dibenzylamine derivative, and method for preparing thereof | KOWA COMPANY, LTD. (JP) | 2014-12-09 | — | — | US | disclosed |
| EP-2626351-A1 | AGENT FOR INHIBITING EXPRESSION OF LIPID METABOLISM RELATED MRNA | Kowa Co., Ltd. (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-20130190540-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE 1-BROMO-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHANE | KOWA COMPANY, LTD. (JP) | 2013-07-25 | — | — | US | disclosed |
| WO-2013080999-A1 | AGENT FOR INHIBITING EXPRESSION OF NPC1L1 AND/OR LIPG MRNA AND AGENT FOR PREVENTING AND/OR TREATING OBESITY | 興和株式会社 (JP) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013081087-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE COMPOUND | 興和株式会社 (JP) | 2013-06-06 | — | — | WO | disclosed |
| EP-2597079-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 1-BROMO-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHANE | Kowa Company Ltd. (JP) | 2013-05-29 | — | — | EP | disclosed |
| EP-2578574-A1 | OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE, AND MANUFACTURING METHOD FOR SAME | Kowa Company, Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| EP-2578574-A1 | OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE, AND MANUFACTURING METHOD FOR SAME | Kowa Company, Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| WO-2012046681-A1 | AGENT FOR INHIBITING EXPRESSION OF LIPID METABOLISM RELATED MRNA | 興和株式会社 (JP) | 2012-04-12 | — | — | WO | disclosed |
| WO-2011152508-A1 | OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE, AND MANUFACTURING METHOD FOR SAME | 興和株式会社 (JP) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190540-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE 1-BROMO-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHANE | RPP30, BRPF1, ALK | TACR1 747/4885IDO1 4293/4885TDO2 3103/4885 |
| US-20150320748-A1 | AGENT FOR INHIBITING EXPRESSION OF LIPID METABOLISM RELATED MRNA | SREBF1, SCD, SREBF2 | TACR1 1795/4885IDO1 2359/4885TDO2 4681/4885 |
| US-20150306098-A1 | AGENT FOR INHIBITING EXPRESSION OF LIPID METABOLISM RELATED MRNA | SREBF1, SCD, SREBF2 | TACR1 1795/4885IDO1 2359/4885TDO2 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.